Literature DB >> 12444356

Detection of substance use disorders in patients presenting with depression.

Robert Mallin1, Kathryn Slott, Martha Tumblin, Melissa Hunter.   

Abstract

Comorbidity between substance use disorders and major depression may complicate the treatment and adversely affect the outcome of either disorder. This study examines the frequency with which patients presenting with depression are evaluated for a substance use disorder in a university-based family medicine residency program. A retrospective chart review was performed to identify 200 patients age 18 and older, seen between June 1, 1989, and June 1, 1999, who were diagnosed with depression (DSM IV code 300.4 or 311.0). The records were divided into two strata based on whether they were seen by resident or faculty physicians. The records were then reviewed for evidence of substance use screening. The overall percentage of patients with depression and evaluated for substance use disorders was calculated, and further stratified as to gender, age, previous psychiatric diagnosis, and previous substance use disorder diagnosis. Family physicians evaluated outpatients with a diagnosis of depression for substance use disorders only 24.5% of the time. Faculty evaluated depressed patients 18%, compared to residents doing so in 31% of patients. Male patients were evaluated 34.7% as compared to 21.2% of females. Patients over age 70 were screened at a rate of only 10.7%. Given the observed prevalence of substance use disorders in patients with a diagnosis of depression is between 40 and 50%, our finding that our depressed patients were evaluated for substance use disorders only 24.5% of the time, suggests that family physicians may be missing a significant number of patients with comorbid disease.

Entities:  

Mesh:

Year:  2002        PMID: 12444356     DOI: 10.1080/08897070209511481

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


  6 in total

1.  Meta-analysis of self-reported substance use compared with laboratory substance assay in general adult mental health settings.

Authors:  Matthew M Large; Glen Smith; Grant Sara; Michael B Paton; Karina Karolina Kedzior; Olav B Nielssen
Journal:  Int J Methods Psychiatr Res       Date:  2012-02-27       Impact factor: 4.035

2.  Measurement-based care for refractory depression: a clinical decision support model for clinical research and practice.

Authors:  Madhukar H Trivedi; Ella J Daly
Journal:  Drug Alcohol Depend       Date:  2007-02-22       Impact factor: 4.492

3.  Reductions in stress and depressive symptoms in mothers of substance-exposed infants, participating in a psychosocial program.

Authors:  Janet K Kern; Emily Y West; Bruce D Grannemann; Tracy L Greer; Laura M Snell; Lori L Cline; Toosje T VanBeveren; Stephen F Heartwell; Beverly A Kleiber; Madhukar H Trivedi
Journal:  Matern Child Health J       Date:  2004-09

4.  Changing profile of abused substances by older persons entering treatment.

Authors:  Michelle R Lofwall; Alyson Schuster; Eric C Strain
Journal:  J Nerv Ment Dis       Date:  2008-12       Impact factor: 2.254

5.  Screening for substance use disorders in neurodevelopmental disorders: a clinical routine?

Authors:  Margita Palmqvist; Gunnar Edman; Sven Bölte
Journal:  Eur Child Adolesc Psychiatry       Date:  2013-08-15       Impact factor: 4.785

6.  Marijuana Use and Depressive Symptoms; Gender Differences in African American Adolescents.

Authors:  Shervin Assari; Ritesh Mistry; Cleopatra Howard Caldwell; Marc A Zimmerman
Journal:  Front Psychol       Date:  2018-11-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.